Test Price
2,800 AED✅ Home Collection Available
KCTD3-Related Neurodevelopmental Disorder – Genetic Test (NGS) in Dubai | DNA Labs UAE
Executive Summary & Core Metrics
This test utilizes next-generation sequencing (NGS) technology to detect pathogenic variants in the KCTD3 gene with a diagnostic sensitivity exceeding 99.9%. A complimentary post-result genetic counseling session is provided to ensure comprehensive understanding of familial recurrence risks. All services comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Guaranteed Precision: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited laboratory.
- VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection: Available daily from 8 AM to 11 PM.
- Immediate Medical Guidance: Telephonic post-test interpretation session with a consultant medical geneticist.
- Insurance Direct Billing: Verify your coverage via WhatsApp +971 54 548 731.
Test Overview & Methodology
The KCTD3 gene next-generation sequencing test detects pathogenic variants associated with autosomal recessive neurodevelopmental disorder, characterized by intellectual disability, epilepsy, and developmental delay. This comprehensive genetic analysis provides an accurate molecular diagnosis, enabling targeted clinical management and recurrence risk assessment for affected families.
| Features | Our Test – KCTD3 NGS Panel | Closest Alternative – Sanger Sequencing |
|---|---|---|
| Precision | Greater than 99% analytic sensitivity and specificity, full gene coverage including intronic regions | Limited to selected exons; may miss deep intronic or splice-site variants |
| Method | Next-Generation Sequencing (NGS) with Sanger confirmation of all pathogenic and likely pathogenic findings | Sanger sequencing of individual amplicons only |
| Turnaround Time | 3 to 4 Weeks | 6 to 8 Weeks |
| Price | 2,800 AED | Approximately 4,000 AED |
Physician Insight & Safety Protocols
“In my practice, I interpret KCTD3 gene results within the full context of clinical history, neurological examination findings, and family pedigree. A pathogenic variant confirms the molecular diagnosis, but a negative result does not exclude other genetic or acquired etiologies. I strongly recommend that every patient and family undergo pre- and post-test genetic counseling to fully understand the implications of the result before any clinical decisions are made.” – Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403.
Important Clinical Advisory
Never discontinue or alter prescribed antiseizure or developmental medications without consulting your treating physician. Genetic test results are intended to complement, not replace, ongoing clinical monitoring and emergency neurological care.
Exclusion Criteria & Emergency Red Flags
- This test is not offered to asymptomatic minors without informed parental consent and prior genetic counseling, in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Non-paternity or forensic identity testing is not available without a valid UAE court order.
- Red Flag: Sudden onset of uncontrolled seizures, loss of previously acquired developmental milestones, or encephalopathy requires immediate emergency evaluation — do not wait for genetic results.
- Individuals with active bleeding disorders or recent blood transfusion (within 4 weeks) may require modified sample collection procedures.
Patient FAQ & Clinical Guidance
1. What is the KCTD3 NGS test and who should consider it?
This test screens the entire KCTD3 gene for pathogenic variants responsible for neurodevelopmental delay, seizures, and intellectual disability. It is appropriate for children and adults with unexplained developmental regression, epilepsy, or a positive family history. The result guides diagnosis, recurrence risk assessment, and clinical management.
2. How is the sample collected and how long do results take?
A standard peripheral whole blood sample is collected by our VIP mobile phlebotomy service using a temperature-controlled cold chain. The next-generation sequencing workflow takes 3 to 4 weeks from sample accession. Urgent preliminary findings can be communicated within 10 working days if clinically necessary.
3. What do I do after receiving the genetic report?
Book a complimentary telephonic interpretation session with our consultant medical geneticist to understand the report clinical significance and family implications. The genetic counselor will explain whether the variant is pathogenic, likely pathogenic, or of uncertain significance, and will coordinate referral to a pediatric neurologist if needed.
4. Does insurance cover the cost of this genetic test?
Coverage varies by insurance provider and policy. We offer direct billing verification via WhatsApp at +971 54 548 731. Our team will check your eligibility and inform you of any co-payment or deductible before sample collection.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance Framework
This genetic testing service operates under the regulatory oversight of the Dubai Health Authority (DHA Facility License Number: 1143) and adheres strictly to:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) — governing the collection, processing, and storage of your genetic and personal data.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields — ensuring secure electronic health information exchange and telemedicine practices.
- Federal Decree-Law No. 4 of 2016 on Medical Liability — safeguarding patient consent, clinical safety, and professional accountability.
Your genetic data is encrypted, access-controlled, and never shared with third parties without your explicit written consent. You have the right to request data deletion in accordance with PDPL Article 9.
Clinical & Logistical Metadata
| Test Name | KCTD3-Related Neurodevelopmental Disorder – Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood |
| Methodology Used | Next-Generation Sequencing (NGS) with Sanger Confirmation |
| ICD-10-CM Code | F84.9, G40.909, F70 |
| LOINC Code | 21636-6 |
| DHA Facility License & Laboratory Address | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians